Should I Buy Recursion Pharmaceuticals (RXRX)? Finance YouTuber Analysis

The YouTuber recommends buying Recursion Pharmaceuticals due to its potential to revolutionize drug discovery using AI, which could significantly lower costs for big pharma companies facing patent cliffs. Despite being unprofitable and having high valuation metrics, the company has partnerships with major drug makers and expected revenue growth, making the potential market worth the risk.

“But the potential market for this and that valuation very much worth the risk for investors.”

The analyst is holding Recursion Pharmaceuticals, noting Nvidia's continued investment despite the stock being down 37% over the last year. He sees significant opportunity in its AI-driven drug discovery platform, which aims to revolutionize the process by enabling faster failure and lower development costs. The company has partnerships with major drugmakers and several programs in pipeline trials, with results expected within two quarters.

“Recursion could revolutionize drug discovery through its language model workflow engine, performing complex drug discovery tasks using a natural language interface.”

The YouTuber recommends Recursion Pharmaceuticals, an AI stock aiming to revolutionize drug discovery by using language models and AI to accelerate the identification of effective compounds. He emphasizes its potential to significantly lower drug development costs for big pharma, its pipeline of programs, and strategic investments from Nvidia and partnerships with major healthcare companies.

“Nvidia recently invested in the company with a $50 million Equity investment and is providing Priority Access to hardware and resources ruran also has Partnerships with major Healthcare companies like Bayer and jentech for research driving 58 million dollar in sales this year.”

Nvidia has invested in Recursion Pharmaceuticals, which is leveraging AI for drug discovery. The company shows potential in the biotech sector, with expected revenue growth, though its stock performance can be volatile based on breakthroughs or approvals.

“recursion Pharmaceuticals ticker rxrx is down the most down 26% since June with Nvidia owning 7.7 million shares worth $45 million of the $2 billion company recursion is leading in the race to decode biology with its language model to perform those complex drug Discovery tasks using artificial intelligence like most biotech stocks the potential is there but it comes and fits and starts when the company announces a breakthrough or an FDA approval or a deal with another company revenue is expected up 57% this year though followed by 9% next but this can turn fast with just one Discovery”

The YouTuber is buying Recursion Pharmaceuticals due to its groundbreaking AI-driven approach to drug discovery, which could significantly lower costs for big pharma. The company uses AI models to screen compounds and 'fail faster,' with six programs in pipeline trials. Nvidia has invested $50 million and provides priority access to hardware, and analysts have price targets suggesting a doubling of the current stock price.

“through the use of AI recursion could dramatically lower cost for drug development and an advantage that would be worth tens of billions of dollars to Big Pharma companies”

The YouTuber recommends Recursion Pharmaceuticals for its potential to revolutionize drug discovery through AI. The company's AI models aim to significantly lower drug development costs, making it an attractive acquisition target for Big Pharma. Despite current losses, strong revenue growth and strategic investments from Nvidia and partnerships with major healthcare companies provide confidence.

“Recursion is leading in the race to decode biology and recently announced its language model orchestrated workflow engine or low to perform complex drug Discovery tasks using a natural language interface.”

The YouTuber highlights Recursion Pharmaceuticals as a leader in AI-driven drug discovery, using its 'low' engine and massive datasets to accelerate compound screening and reduce development costs. With Nvidia's investment and partnerships with major healthcare companies, it has strong intellectual property and a pipeline of programs, despite not yet being profitable.

“I highlighted recursion Pharmaceuticals ticker rxrx as a potential 10x stock in a recent video recursion is leading in the race to decode biology and recently announced its language model orchestrated workflow engine or low to perform complex drug Discovery tasks using a natural language interface.”

The YouTuber highlights Nvidia's substantial stake in Recursion Pharmaceuticals, viewing it as a pure return play on AI drug discovery. The company's language model for drug discovery, strong balance sheet, and intellectual property make it a promising investment in a high-growth sector, despite current unprofitability.

“AI drug Discovery is one of the most promising and talked about themes within that larger Trend helping to reduce billions in costs for drug development”

The YouTuber recommends Recursion Pharmaceuticals as a play on AI drug discovery, noting its leadership in decoding biology with its language model orchestrated workflow engines. He highlights its strong balance sheet and intellectual property, suggesting it could be a takeover target despite not yet being profitable.

“one of my favorite plays on this AI drug Discovery theme is recursion Pharmaceuticals ticker rxrx recursion is leading in that race to decode biology”

The YouTuber recommends Recursion Pharmaceutical as a play on AI drug discovery, highlighting its language model orchestrated workflow engine and strong intellectual property. Despite not being profitable, it has a strong balance sheet and could be a takeover target.

“Recursion is leading in that race to decode biology and recently announced its language model orchestrated workflow engine that low to perform complex drug Discovery tasks using a natural language interface.”

The speaker highlights Recursion as a company making significant strides in drug discovery, particularly in leveraging AI. They are achieving milestones that are surprising to many, indicating strong progress and potential for future growth in the healthcare space.

“in the public markets there are also companies recursion absi we featured uh prominently and you know they're doing amazing things and uh you know hitting Milestones I think that are surprising to people”

The YouTuber suggests buying Recursion Pharmaceuticals because it is reportedly in Nvidia's crosshairs for acquisition. He believes that if Nvidia buys it, the stock could easily 10x, similar to what happened with ARM Holdings after Nvidia's interest.

“Put this on your radar ticker symbol rxrx recursion Pharmaceuticals is is in the crosshairs of Nvidia this one guys is sitting at $9.38”